Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination

Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma. Immune-related cardiovascular toxicity—myocarditis and pericarditis—are k...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Takahiro Niimura, Mitsuhiro Goda, Koji Miyata, Jun Matsumoto, Toshihiko Yoshioka, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami, Keisuke Ishizawa
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2023-08-01
Sarja:	Frontiers in Drug Safety and Regulation
Aiheet:	atezolizumab bevacizumab cardiovascular toxicity thromboembolism adverse event
Linkit:	https://www.frontiersin.org/articles/10.3389/fdsfr.2023.1213771/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!